Every year, more than 3,000 scientific abstracts are accepted for oral and poster presentation at the Society's annual meeting.
Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to biomedical research
Published on: January 30, 2014
Work with the Food and Drug Administration (FDA) – ASH continues to alert FDA about new hematology/oncology drug shortages. ASH also provides the Society’s members with real-time updates from the FDA about hematologic drug shortages through ASH’s e-publications and Drug Shortage Information page.
Over the past year, ASH submitted comments to the FDA on its draft strategic plan and recently submitted feedback to the Agency on its proposed advanced notification requirements for drug and biologic shortages. ASH has also met with FDA leaders to discuss the importance of including biological products under the advanced notification requirements authorized by the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012. ASH’s advocacy was instrumental to ensuring the inclusion of biologics in two guidance documents the FDA released on October 31, 2013: (1) the Agency’s strategic plan to enhance its response to preventing and mitigating shortages of drugs and biologics; and (2) a proposed rule requiring all manufacturers of certain medically important prescription drugs and biological products to notify the FDA of a permanent discontinuance or a temporary interruption of manufacturing likely to disrupt their supply.
Work with Congress – ASH continues to work with Congress on drug shortages. The Society will also review and analyze new legislation that is introduced to address the economic aspects of drug shortages.
Support the mission of ASH and help move hematology forward.
Become part of a global network of more than 15,000 hematologists working to conquer blood diseases.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology